Abstract
Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p < 0.02), and overall survival (p < 0.005) when compared with clinical stage III cats.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylmuramyl-Alanyl-Isoglutamine / analogs & derivatives*
-
Acetylmuramyl-Alanyl-Isoglutamine / therapeutic use
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / mortality
-
Adenocarcinoma / surgery
-
Adenocarcinoma / veterinary*
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Cat Diseases / drug therapy*
-
Cat Diseases / mortality
-
Cat Diseases / surgery
-
Cats
-
Chemotherapy, Adjuvant
-
Disease-Free Survival
-
Double-Blind Method
-
Female
-
Follow-Up Studies
-
Infusions, Intravenous
-
Liposomes
-
Male
-
Mammary Neoplasms, Animal / drug therapy*
-
Mammary Neoplasms, Animal / mortality
-
Mammary Neoplasms, Animal / surgery
-
Mastectomy, Radical
-
Neoplasm Staging
-
Phosphatidylethanolamines / therapeutic use*
-
Survival Rate
Substances
-
Antineoplastic Agents
-
Liposomes
-
Phosphatidylethanolamines
-
mifamurtide
-
Acetylmuramyl-Alanyl-Isoglutamine